Generic Name and Formulations:
Ceftazidime 500mg, 1g, 2g; IM or IV inj; sodium content 2.3mEq/g.
Indications for FORTAZ:
Susceptible infections including septicemia, pneumonia, skin and skin structure, bone and joint, gynecologic, intraabdominal, meningitis, urinary tract.
Uncomplicated UTIs: 250mg IV or IM every 12hrs. Complicated UTIs: 500mg IV or IM every 8–12hrs. Uncomplicated pneumonia, mild skin or skin structure: 500mg–1g IV or IM every 8hrs. Bone and joint: 2g IV every 12hrs. Serious gynecologic, intraabdominal, meningitis, or very severe life-threatening (esp. immunocompromised): 2g IV every 8hrs. Lung infections by Pseudomonas in cystic fibrosis: 30–50mg/kg IV every 8hrs (max 6g/day). Renal impairment: CrCl 31–50mL/min: 1g every 12hrs; CrCl 16–30mL/min: 1g every 24hrs; CrCl 6–15mL/min: 500mg every 24hrs; CrCl <5mL/min: 500mg every 48hrs. Hemodialysis: 1g loading dose then 1g after dialysis session. Peritoneal dialysis: 1g loading dose then 500mg every 24hrs.
Neonates: 30mg/kg IV every 12hrs. 1mo–12yrs: 30–50mg/kg IV every 8hrs (max 6g/day). Renal impairment: reduce dose.
Penicillin or other allergy. Renal impairment; see Adult. Monitor prothrombin time in renal or hepatic dysfunction, poor nutritional states, or long-term use. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
May potentiate nephrotoxicity of aminoglycosides or diuretics. Antagonized by chloramphenicol. False (+) glucose test with Clinitest, Benedict's, or Fehling's soln.
Hypersensitivity reactions (eg, rash, pruritus, fever), local reactions, GI upset, elevated liver enzymes; C. difficile-associated diarrhea.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds